Macrocyclic Peptides Inhibit HCV NS3 Protease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Hepatitis C virus (HCV) infection, particularly targeting the NS3 protease, are not effective for a substantial fraction of patients, highlighting a need for more potent antiviral compounds that can inhibit the NS3 protease function effectively across various genotypes.
Innovation Solution
Development of macrocyclic compounds that specifically inhibit the NS3 protease, potentially in combination with other antiviral agents, to treat HCV infection by targeting the NS3 protease and other viral components, such as NS4A, metalloprotease, or polymerase.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current HCV therapy (alpha-interferon and ribavirin combination) is used, then treatment coverage is achieved, but sustained efficacy is only obtained in 40% of patients
Solution Approach 1:
The patent employs parameter changes by developing novel macrocyclic compounds with modified chemical structures (Formula I with specific R groups and substituents) that target the NS3 protease with enhanced potency and selectivity compared to existing therapies, thereby improving sustained efficacy while maintaining broad treatment coverage
Solution Approach 2:
The patent creates composite therapeutic strategies by combining the macrocyclic NS3 protease inhibitor with other antiviral agents targeting different viral components (NS4A, metalloprotease, polymerase), forming a multi-target composite therapy that overcomes the limitations of single-agent treatment and achieves both high efficacy and broad coverage
2Reliability
If macrocyclic compounds are designed to specifically inhibit NS3 protease, then antiviral activity is enhanced, but compound complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the macrocyclic compound into distinct functional modules (Formula I with defined R1-R6 substituents and ring structures), where each segment contributes specific properties such as protease binding affinity, metabolic stability, or solubility, allowing rational optimization of antiviral activity while managing molecular complexity
Solution Approach 2:
The patent achieves universality by designing a macrocyclic core structure (Formula I) that can accommodate various substituent patterns (R groups) to target different HCV genotypes and potentially other flaviviruses, making the compound class broadly applicable while maintaining a manageable structural framework
Data Source
AI summary
Macrocyclic peptides are disclosed having the general formula (I) wherein R3, R3', R4, R6, R', X, Q and W are described. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.